0000874716IDEXX LABORATORIES INC /DEfalse00008747162021-05-122021-05-12



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): May 12, 2021
IDEXX LABORATORIES INC /DE
 
  
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
IDEXX LABORATORIES INC /DE 
Delaware000-1927101-0393723
(State or other jurisdiction(Commission File Number)(IRS Employer Identification No.)
of incorporation) 
One IDEXX Drive Westbrook,Maine04092
(Address of principal executive offices)(ZIP Code)
0000874716
207.556.0300
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.10 par value per shareIDXXNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (ß230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (ß240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨





Item 5.07.
Submission of Matters to a Vote of Security Holders.
On May 12, 2021, IDEXX Laboratories, Inc. (the “Company”) held its 2021 annual meeting of shareholders (the “Annual Meeting”). At the Annual Meeting, shareholders considered and voted on the following proposals, each of which is described in more detail in the Company’s proxy statement dated March 31, 2021, (the "Proxy Statement"): (1) the election of Daniel M. Junius as a Class II director, for a term that expires at the 2023 annual meeting of shareholders, and Bruce L. Claflin, Asha S. Collins, PhD and Sam Samad each as Class I directors, for terms expiring at the 2024 annual meeting of shareholders; (2) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered accounting firm for the current fiscal year; and (3) the approval, on an advisory basis, of the compensation of the Company's named executive officers as presented in the Proxy Statement delivered to shareholders in connection with the Annual Meeting.

The voting results at the Annual Meeting with respect to each of the matters described above, were as follows:

Proposal One:Election of Directors

Nominees

For

Against

Abstain

Broker Non-Votes
Bruce L. Claflin67,436,7722,861,27360,1226,378,832
Asha S. Collins, PhD67,802,4842,502,56653,1176,378,832
Daniel M. Junius69,481,500822,36254,3056,378,832
Sam Samad69,493,423809,39055,3546,378,832


Proposal Two:Ratification of Appointment of Independent Registered Public Accounting Firm
For74,352,030 
Against2,342,427 
Abstain42,542 
Broker Non-VotesN/A


Proposal Three:Advisory Vote to Approve Executive Compensation
For66,390,797
Against3,860,320
Abstain107,050
Broker Non-Votes6,378,832




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEXX LABORATORIES, INC.
Date: May 18, 2021By:/s/ Sharon E. Underberg
Sharon E. Underberg
Senior Vice President, General Counsel and Corporate Secretary